Sex differences in the pharmacokinetics and pharmacodynamics of antidepressants: An updated review

Gender Medicine

Volumn 6, Issue 4, 2009, Pages 522-543

  Bigos, Kristin L ^a   Pollock, Bruce G ^b,c,d   Stankevich, Beth A ^a   Bies, Robert R ^b,d,e  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^e UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

antidepressant; gender; pharmacodynamics; pharmacokinetics; sex; SSRI

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DESVENLAFAXINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; ISOCARBOXAZID; MAPROTILINE; MIRTAZAPINE; NEFAZODONE; NORCITALOPRAM; NORFLUOXETINE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PLACEBO; REBOXETINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; VENLAFAXINE;

ALCOHOLISM; AREA UNDER THE CURVE; BEHAVIOR DISORDER; CLINICAL TRIAL; CONGENITAL MALFORMATION; DEMENTIA; DEPRESSION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESPONSE; DRUG WITHDRAWAL; DYSTHYMIA; ENZYME SUBSTRATE COMPLEX; ESTROGEN ACTIVITY; HUMAN; HYDROCORTISONE BLOOD LEVEL; MAJOR DEPRESSION; OBSESSIVE COMPULSIVE DISORDER; PREGNANCY; PRENATAL EXPOSURE; PRIORITY JOURNAL; PUERPERAL DEPRESSION; QT PROLONGATION; REVIEW; RISK ASSESSMENT; SEX DIFFERENCE; SIDE EFFECT; SINGLE DRUG DOSE; SPONTANEOUS ABORTION; UNSPECIFIED SIDE EFFECT; WITHDRAWAL SYNDROME;

ANTIDEPRESSIVE AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DEPRESSION; FEMALE; HUMANS; MALE; SEX FACTORS;

EID: 74549176824     PISSN: 15508579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.genm.2009.12.004     Document Type: Review

References (132)

1. Bennett J.C. Inclusion of women in clinical trials-policies for population subgroups. N Engl J Med. 329 (1993) 288-292
2. Merkatz R.B., Temple R., Subel S., et al., Working Group on Women in Clinical Trials. Women in clinical trials of new drugs. A change in Food and Drug Administration policy. N Engl J Med. 329 (1993) 292-296
3. Harris R.Z., Benet L.Z., and Schwartz J.B. Gender effects in pharmacokinetics and pharmacodynamics. Drugs. 50 (1995) 222-239
4. Regier D.A., Narrow W.E., Rae D.S., et al. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry. 50 (1993) 85-94
5. Kornstein S.G., Schatzberg A.F., Thase M.E., et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry. 157 (2000) 1445-1452
6. Schmucker D.L., and Vesell E.S. Underrepresentation of women in clinical drug trials. Clin Pharmacol Ther. 54 (1993) 11-15
7. Hamilton J., and Parry B. Sex-related differences in clinical drug response: Implications for women's health. J Am Med Womens Assoc. 38 (1983) 126-132
8. Stewart D.E. Are there special considerations in the prescription of serotonin reuptake inhibitors for women?. Can J Psychiatry. 43 (1998) 900-904
9. Bies R.R., Bigos K.L., and Pollock B.G. Gender and antidepressants. In: Legato M.J. (Ed). Principles of Gender-Specific Medicine Vol 2 (2004), Elsevier Academic Press, Boston, Mass 860-868
10. Bies R.R., Bigos K.L., and Pollock B.G. Gender differences in the pharmacokinetics and pharmacodynamics of antidepressants. J Gend Specif Med. 6 (2003) 12-20
11. Physicians' Desk Reference. 63rd ed. (2009), Physicians' Desk Reference Inc, Montvale, NJ
12. Kornstein S.G., Sloan D.M., and Thase M.E. Genderspecific differences in depression and treatment response. Psychopharmacol Bull. 36 (2002) 99-112
13. Rapaport M.H., Thompson P.M., Kelsoe Jr. J.R., et al. Gender differences in outpatient research subjects with affective disorders: A comparison of descriptive variables. J Clin Psychiatry. 56 (1995) 67-72
14. Hirschfeld R.M., and Russell J.M. Assessment and treatment of suicidal patients. N Engl J Med. 337 (1997) 910-915
15. Fegert J.M., Kölch M., Zito J.M., et al. Antidepressant use in children and adolescents in Germany. J Child Adolesc Psychopharmacol. 16 (2006) 197-206
16. Gotlib I.H., Whiffen V.E., Mount J.H., et al. Prevalence rates and demographic characteristics associated with depression in pregnancy and the postpartum. J Consult Clin Psychol. 57 (1989) 269-274
17. Thompson D.S., and Pollock B.G. Psychotropic metabolism: Gender-related issues. Psychiatr Times 18 (2001) 46-48
18. Yonkers K.A., and March D. Treatment of premenstrual dysphoric disorder. Mental Fitness. 2 (2003) 20-28
19. Wikander I., Sundblad C., Andersch B., et al. Citalopram in premenstrual dysphoria: Is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle?. J Clin Psychopharmacol. 18 (1998) 390-398
20. Young S.A., Hurt P.H., Benedek D.M., and Howard R.S. Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: A randomized, double-blind, placebo-controlled crossover trial. J Clin Psychiatry. 59 (1998) 76-80
21. Steiner M., Korzekwa M., Lamont J., and Wilkins A. Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria. Psychopharmacol Bull. 33 (1997) 771-774
22. Sundblad C., Hedberg M.A., and Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: A placebo-controlled trial. Neuropsychopharmacology 9 (1993) 133-145
23. Halbreich U., and Smoller J.W. Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J Clin Psychiatry. 58 (1997) 399-402
24. Alpay F.B., and Turhan N.O. Intermittent versus continuous sertraline therapy in the treatment of premenstrual dysphoric disorders. Int J Fertil Womens Med. 46 (2001) 228-231
25. Fisar Z., Kalisová L., Paclt I., et al. Platelet serotonin uptake in drug-naive depressive patients before and after treatment with Citalopram. Psychiatry Res. 161 (2008) 185-194
26. Cotterchio M., Kreiger N., Darlington G., and Steingart A. Antidepressant medication use and breast cancer risk. Am J Epidemiol. 151 (2000) 951-957
27. Thompson D.S., Kirshner M.A., Klug T.L., et al. A preliminary study of the effect of fluoxetine treatment on the 2:16-alpha-hydroxyestrone ratio in young women. Ther Drug Monit. 25 (2003) 125-128
28. Rossouw J.E., Anderson G.L., Prentice R.L., et al., Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
29. Hlatky M.A., Boothroyd D., Vittinghoff E., et al., Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: Results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. JAMA 287 (2002) 591-597
30. Kelly J.P., Rosenberg L., Palmer J.R., et al. Risk of breast cancer according to use of antidepressants, phenothiazines, and antihistamines. Am J Epidemiol. 150 (1999) 861-868
31. Bies R.R., Feng Y., Lotrich F.E., et al. Utility of sparse concentration sampling for citalopram in elderly clinical trial subjects. J Clin Pharmacol. 44 (2004) 1352-1359
32. de Mendonça Lima C.A., Baumann P., Braward-Amey M., et al. Effect of age and gender on citalopram and desmethylcitalopram steady-state plasma concentrations in adults and elderly depressed patients. Prog Neuropsychopharmacol Biol Psychiatry. 29 (2005) 952-956
33. Reis M., Lundmark J., and Bengtsson F. Therapeutic drug monitoring of racemic citalopram: A 5-year experience in Sweden, 1992-1997. Ther Drug Monit. 25 (2003) 183-191
34. Reis M., Olsson G., Carlsson B., et al. Serum levels of citalopram and its main metabolites in adolescent patients treated in a naturalistic clinical setting. J Clin Psychopharmacol. 22 (2002) 406-413
35. Reis M., Chermá M.D., Carlsson B., Bengtsson F., and Task Force for TDM of Escitalopram in Sweden. Therapeutic drug monitoring of escitalopram in an outpatient setting. Ther Drug Monit. 29 (2007) 758-766
36. Ferguson J.M., and Hill H. Pharmacokinetics of fluoxetine in elderly men and women. Gerontology. 52 (2006) 45-50
37. Härtter S., Wetzel H., Hammes E., et al. Nonlinear pharmacokinetics of fluvoxamine and gender differences. Ther Drug Monit. 20 (1998) 446-449
38. Preskorn S.H. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet. 32 Suppl 1 (1997) 1-21
39. Feng Y., Pollock B.G., Ferrell R.E., et al. Paroxetine: Population pharmacokinetic analysis in late-life depression using sparse concentration sampling. Br J Clin Pharmacol. 61 (2006) 558-569
40. Findling R.L., Nucci G., Piergies A.A., et al. Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder. Neuropsychopharmacology 31 (2006) 1274-1285
41. Gex-Fabry M., Eap C.B., Oneda B., et al. CYP2D6 and ABCB1 genetic variability: Influence on paroxetine plasma level and therapeutic response. Ther Drug Monit. 30 (2008) 474-482
42. Almeida S., Portolés A., Terleira A., et al. Comparative bioavailability/bioequivalence of two different sertraline formulations: A randomised, 2-period × 2-sequence, crossover clinical trial in healthy volunteers. Arzneimittelforschung 55 (2005) 191-197
43. Physicians' Desk Reference. 57th ed. (2003), Physicians' Desk Reference Inc, Montvale, NJ
44. Ronfeld R.A., Tremaine L.M., and Wilner K.D. Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet. 32 Suppl 1 (1997) 22-30
45. Alderman J., Wolkow R., and Fogel I.M. Drug concentration monitoring with tolerability and efficacy assessments during open-label, long-term sertraline treatment of children and adolescents. J Child Adolesc Psychopharmacol. 16 (2006) 117-129
46. Hildebrandt M.G., Steyerberg E.W., Stage K.B., et al., Danish University Antidepressant Group. Are gender differences important for the clinical effects of antidepressants?. Am J Psychiatry 160 (2003) 1643-1650
47. Mundo E., Pirola R., Bellodi L., et al. Are gender differences in antiobsessional response related to different clomipramine metabolism?. J Clin Psychopharmacol 22 (2002) 341-342
48. Cohen L.G., Biederman J., Wilens T.E., et al. Desipramine clearance in children and adolescents: Absence of effect of development and gender. J Am Acad Child Adolesc Psychiatry 38 (1999) 79-85
49. Dahl M.L., Bertilsson L., and Nordin C. Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: Relationship to the CYP2D6 genotype. Psychopharmacology (Berl) 123 (1996) 315-319
50. Wisner K.L., Perel J.M., and Wheeler S.B. Tricyclic dose requirements across pregnancy. Am J Psychiatry 150 (1993) 1541-1542
51. Gex-Fabry M., Rudaz S., Balant-Gorgia A.E., et al. Steady-state concentration of venlafaxine enantiomers: Model-based analysis of between-patient variability. Eur J Clin Pharmacol 58 (2002) 323-331
52. Stewart J.J., Berkel H.J., Parish R.C., et al. Single-dose pharmacokinetics of bupropion in adolescents: Effects of smoking status and gender. J Clin Pharmacol 41 (2001) 770-778
53. Sweet R.A., Pollock B.G., Kirshner M., et al. Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. J Clin Pharmacol 35 (1995) 876-884
54. Reis M., Prochazka J., Sitsen A., et al. Inter- and intraindividual pharmacokinetic variations of mirtazapine and its N-demethyl metabolite in patients treated for major depressive disorder: A 6-month therapeutic drug monitoring study. Ther Drug Monit 27 (2005) 469-477
55. Timmer C.J., Sitsen J.M., and Delbressine L.P. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet 38 (2000) 461-474
56. Timmer C.J., Paanakker J.E., and Van Hal H.J. Pharmacokinetics of mirtazapine from orally administered tablets: Influence of gender, age and treatment regimen. Hum Psychopharmacol 11 (1996) 497-509
57. Barbhaiya R.H., Buch A.B., and Greene D.S. A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses. J Clin Psychopharmacol 16 (1996) 19-25
58. Prapotnik M., Waschgler R., König P., et al. Therapeutic drug monitoring of trazodone: Are there pharmacokinetic interactions involving citalopram and fluoxetine?. Int J Clin Pharmacol Ther. 42 (2004) 120-124
59. Greenblatt D.J., Friedman H., Burstein E.S., et al. Trazodone kinetics: Effect of age, gender, and obesity. Clin Pharmacol Ther. 42 (1987) 193-200
60. Grossman M.I., Kirsner J.B., and Gillespie I.E. Basal and histalog-stimulated gastric secretion in control subjects and in patients with peptic ulcer or gastric cancer. Gastroenterology 45 (1963) 14-26
61. Hutson W.R., Roehrkasse R.L., and Wald A. Influence of gender and menopause on gastric emptying and motility. Gastroenterology 96 (1989) 11-17
62. Wald A., Van Thiel D.H., Hoechstetter L., et al. Gastrointestinal transit: The effect of the menstrual cycle. Gastroenterology 80 (1981) 1497-1500
63. Greenblatt D.J., Divoll M., Harmatz J.S., and Shader R.I. Oxazepam kinetics: Effects of age and sex. J Pharmacol Exp Ther. 215 (1980) 86-91
64. Greenblatt D.J., Divoll M., Abernethy D.R., and Shader R.I. Physiologic changes in old age: Relation to altered drug disposition. J Am Geriatr Soc. 30 Suppl (1982) S6-S10
65. Flockhart D.A. Drug interactions: Cytochrome P450 drug interaction table. Indiana School of Medicine (2007). http://medicine.iupui.edu/clinpharm/ddis/table.asp Accessed December 1, 2008
66. Meibohm B., Beierle I., and Derendorf H. How important are gender differences in pharmacokinetics?. Clin Pharmacokinet 41 (2002) 329-342
67. Schuetz E.G., Furuya K.N., and Schuetz J.D. I nterindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther. 275 (1995) 1011-1018
68. Pollock B.G., Wylie M., Stack J.A., et al. Inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women. J Clin Pharmacol 39 (1999) 936-940
69. Ford J.M., Truman C.A., Wilcock G.K., and Roberts C.J. Serum concentrations of tacrine hydrochloride predict its adverse effects in Alzheimer's disease. Clin Pharmacol Ther. 53 (1993) 691-695
70. Domecq C., Naranjo C.A., Ruiz I., and Busto U. Sexrelated variations in the frequency and characteristics of adverse drug reactions. Int J Clin Pharmacol Ther Toxicol 18 (1980) 362-366
71. Kashuba A.D., and Nafziger A.N. Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs. Clin Pharmacokinet 34 (1998) 203-218
72. Lane J.D., Steege J.F., Rupp S.L., and Kuhn C.M. Menstrual cycle effects on caffeine elimination in the human female. Eur J Clin Pharmacol 43 (1992) 543-546
73. Aldridge A., Bailey J., and Neims A.H. The disposition of caffeine during and after pregnancy. Semin Perinatol 5 (1981) 310-314
74. Berlanga C., and Flores-Ramos M. Different gender response to serotonergic and noradrenergic antidepressantsA comparative study of the efficacy of citalopram and reboxetine. J Affect Disord 95 (2006) 119-123
75. Naranjo C.A., Bremner K.E., and Lanctôt K.L. Effects of citalopram and a brief psycho-social intervention on alcohol intake, dependence and problems. Addiction 90 (1995) 87-99
76. Cusin C., Fava M., Amsterdam J.D., et al. Early symptomatic worsening during treatment with fluoxetine in major depressive disorder: Prevalence and implications. J Clin Psychiatry 68 (2007) 52-57
77. Papakostas G.I., Miller K.K., Petersen T., et al. Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine. J Clin Psychiatry 67 (2006) 952-957
78. McGrath P.J., Stewart J.W., Quitkin F.M., et al. Predictors of relapse in a prospective study of fluoxetine treatment of major depression. Am J Psychiatry 163 (2006) 1542-1548
79. Bano S., Akhter S., and Afridi M.I. Gender based response to fluoxetine hydrochloride medication in endogenous depression. J Coll Physicians Surg Pak. 14 (2004) 161-165
80. Tsai S.J., Gau Y.T., Hong C.J., et al. Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients. J Affect Disord 113 (2009) 183-187
81. Martényi F., Dossenbach M., Mraz K., and Metcalfe S. Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: A doubleblind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile. Eur Neuropsychopharmacol 11 (2001) 227-232
82. Bruder G.E., Stewart J.W., Tenke C.E., et al. Electroencephalographic and perceptual asymmetry differences between responders and nonresponders to an SSRI antidepressant. Biol Psychiatry 49 (2001) 416-425
83. Naito S., Sato K., Yoshida K., et al. Gender differences in the clinical effects of fluvoxamine and milnacipran in Japanese major depressive patients. Psychiatry Clin Neurosci 61 (2007) 421-427
84. Bogetto F., Bellino S., Revello R.B., and Patria L. Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: A clinical investigation. CNS Drugs 16 (2002) 273-283
85. Baca E., Garcia-Garcia M., and Porras-Chavarino A. Gender differences in treatment response to sertraline versus imipramine in patients with nonmelancholic depressive disorders. Prog Neuropsychopharmacol Biol Psychiatry 28 (2004) 57-65
86. Morishita S., and Kinoshita T. Predictors of response to sertraline in patients with major depression. Hum Psychopharmacol 23 (2008) 647-651
87. Lanctôt K.L., Herrmann N., van Reekum R., et al. Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease. Int J Geriatr Psychiatry 17 (2002) 531-541
88. Mundo E., Bareggi S.R., Pirola R., and Bellodi L. Effect of acute intravenous clomipramine and antiobsessional response to proserotonergic drugs: Is gender a predictive variable?. Biol Psychiatry 45 (1999) 290-294
89. Kornstein S.G., Wohlreich M.M., Mallinckrodt C.H., et al. Duloxetine efficacy for major depressive disorder in male vs. female patients: Data from 7 ran- domized, double-blind, placebo-controlled trials. J Clin Psychiatry 67 (2006) 761-770
90. Mallinckrodt C.H., Watkin J.G., Liu C., et al. Duloxetine in the treatment of major depressive disorder: A comparison of efficacy in patients with and without melancholic features. BMC Psychiatry 5 (2005) 1
91. Thase M.E., Entsuah R., Cantillon M., and Kornstein S.G. Relative antidepressant efficacy of venlafaxine and SSRIs: Sex-age interactions. J Womens Health (Larchmt). 14 (2005) 609-616
92. Halbreich U., Rojansky N., Palter S., et al. Estrogen augments serotonergic activity in postmenopausal women. Biol Psychiatry. 37 (1995) 434-441
93. Halbreich U. Role of estrogen in postmenopausal depression. Neurology. 48 Suppl 7 (1997) S16-S19
94. Halbreich U., and Kahn L.S. Role of estrogen in the aetiology and treatment of mood disorders. CNS Drugs. 15 (2001) 797-817
95. Quitkin F.M., Stewart J.W., McGrath P.J., et al. Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry Suppl. (1993) 30-34
96. Thase M.E., Frank E., Kornstein S.G., and Yonkers K.A. Gender differences in response to treatments of depression. In: Frank E. (Ed). Gender and Its Effect on Psychopathology (2000), American Psychiatric Association Press, Washington, DC 103-129
97. Davidson J., and Pelton S. Forms of atypical depression and their response to antidepressant drugs. Psychiatry Res. 17 (1986) 87-95
98. Raskin A. Age-sex differences in response to antidepressant drugs. J Nerv Ment Dis. 159 (1974) 120-130
99. Pastuszak A., Schick-Boschetto B., Zuber C., et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA. 269 (1993) 2246-2248
100. Wisner K.L., Gelenberg A.J., Leonard H., et al. Pharmacologic treatment of depression during pregnancy. JAMA. 282 (1999) 1264-1269
101. Wisner K.L., Zarin D.A., Holmboe E.S., et al. Riskbenefit decision making for treatment of depression during pregnancy. Am J Psychiatry. 157 (2000) 1933-1940
102. Sanz E.J., De-las-Cuevas C., Kiuru A., et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: A database analysis. Lancet. 365 (2005) 482-487
103. Williams M., and Wooltorton E. Paroxetine (Paxil) and congenital malformations. CMAJ. 173 (2005) 1320-1321
104. Cole J.A., Modell J.G., Haight B.R., et al. Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf. 16 (2007) 474-484
105. Bérard A., Ramos E., Rey E., et al. First trimester exposure to paroxetine and risk of cardiac malformations in infants: The importance of dosage. Birth Defects Res B Dev Reprod Toxicol. 80 (2007) 18-27
106. Cole J.A., Ephross S.A., Cosmatos I.S., and Walker A.M. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf. 16 (2007) 1075-1085
107. Bar-Oz B., Einarson T., Einarson A., et al. Paroxetine and congenital malformations: Meta-analysis and consideration of potential confounding factors. Clin Ther. 29 (2007) 918-926
108. O'Brien L., Einarson T.R., Sarkar M., et al. Does paroxetine cause cardiac malformations?. J Obstet Gynaecol Can. 30 (2008) 696-701
109. Oberlander T.F., Warburton W., Misri S., et al. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry. 63 (2006) 898-906
110. Suri R., Altshuler L., Hellemann G., et al. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatry. 164 (2007) 1206-1213
111. Chambers C.D., Hernandez-Diaz S., Van Marter L.J., et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 354 (2006) 579-587
112. Källén B., and Olausson P.O. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf. 17 (2008) 801-806
113. Lennestål R., and Källén B. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol. 27 (2007) 607-613
114. Louik C., Lin A.E., Werler M.M., et al. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med. 356 (2007) 2675-2683
115. Ferreira E., Carceller A.M., Agogué C., et al. Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics. 119 (2007) 52-59
116. Dubnov-Raz G., Juurlink D.N., Fogelman R., et al. Antenatal use of selective serotonin-reuptake inhibitors and QT interval prolongation in newborns. Pediatrics. 122 (2008) e710-e715
117. Salkeld E., Ferris L.E., and Juurlink D.N. The risk of postpartum hemorrhage with selective serotonin reuptake inhibitors and other antidepressants. J Clin Psychopharmacol. 28 (2008) 230-234
118. Djulus J., Koren G., Einarson T.R., et al. Exposure to mirtazapine during pregnancy: A prospective, comparative study of birth outcomes. J Clin Psychiatry. 67 (2006) 1280-1284
119. Maschi S., Clavenna A., Campi R., et al. Neonatal outcome following pregnancy exposure to antidepressants: A prospective controlled cohort study. BJOG. 115 (2008) 283-289
120. Chun-Fai-Chan B., Koren G., Fayez I., et al. Pregnancy outcome of women exposed to bupropion during pregnancy: A prospective comparative study. Am J Obstet Gynecol. 192 (2005) 932-936
121. Pearson K.H., Nonacs R.M., Viguera A.C., et al. Birth outcomes following prenatal exposure to antidepressants. J Clin Psychiatry. 68 (2007) 1284-1289
122. Ramos E., St-André M., Rey E., et al. Duration of antidepressant use during pregnancy and risk of major congenital malformations. Br J Psychiatry. 192 (2008) 344-350
123. Ericson A., Källén B., and Wiholm B. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol. 55 (1999) 503-508
124. Kulin N.A., Pastuszak A., Sage S.R., et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: A prospective controlled multicenter study. JAMA. 279 (1998) 609-610
125. Davis R.L., Rubanowice D., McPhillips H., et al., HMO Research Network Center for Education, Research in Therapeutics. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf. 16 (2007) 1086-1094
126. Einarson A., Pistelli A., DeSantis M., et al. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy [published correction appears in Am J Psychiatry. 2008;165:777, 1208]. Am J Psychiatry 165 (2008) 749-752
127. Marcus S.M., and Heringhausen J.E. Depression in childbearing women: When depression complicates pregnancy. Primary Care 36 (2009) 151-165
128. Marcus S.M., and Heringhausen J.E. Depression in childbearing women: When depression complicates pregnancy. Primary Care 36 (2009) ix
129. Loebstein R., and Koren G. Pregnancy outcome and neurodevelopment of children exposed in utero to psychoactive drugs: The Motherisk experience. J Psychiatry Neurosci. 22 (1997) 192-196
130. Marcus S.M. Depression during pregnancy: Rates, risks and consequences - Motherisk Update 2008. Can J Clin Pharmacol. 16 (2009) e15-e22
131. Bigos K.L., Bies R.R., and Pollock B.G. Population pharmacokinetics in geriatric psychiatry. Am J Geriatr Psychiatry. 14 (2006) 993-1003
132. Bigos K.L., Pollock B.G., Coley K.C., et al. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol. 48 (2008) 157-165